Citi analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE